首页> BMJ open respiratory research> Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access.

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access.

导出 LinkOut

翻译打印收藏纠错

第一作者： Caroline,O'Leary

第一单位： Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.

作者： Caroline,O'Leary ^[1] ; Christopher,Schultz ^[2] ; Cathal,Walsh ^[3] ; Roisin,Adams ^[3] ; Deborah,Casey ^[1] ; Stephen,Lane ^[4] ; Michael,Harrison ^[5] ; Shane,Doyle ^[3] ; Richard W,Costello ^[6] ; Fionnuala,King ^[3] ; Desmond M,Murphy ^[7]

作者单位： Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland. ^[1] HSE Acute Operations, Quality and Patient Safety, Dublin, Ireland. ^[2] Acute Hospitals Drugs Management Programme, Dublin, Ireland. ^[3] Department of Respiratory Medicine, Tallaght University Hospital & Peamount Healthcare, Dublin, Ireland. ^[4] Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland. ^[5] Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. ^[6] Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland desmond.murphy@hse.ie.;The HRB Clinical Research Facility, University College Cork, Cork, Ireland. ^[7]

关键词 Asthma Cytokine Biology Eosinophil Biology Pulmonary eosinophilia

医学主题词肾上腺皮质激素类(Adrenal Cortex Hormones);抗哮喘药(Anti-Asthmatic Agents);哮喘(Asthma);队列研究(Cohort Studies);嗜酸粒细胞增多(Eosinophilia);人类(Humans);回顾性研究(Retrospective Studies)

DOI 10.1136/bmjresp-2022-001341

PMID 36167473

发布时间 2022-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交